Jeremy Levin, DPhil, MB BChir
Jeremy Levin, DPhil, MB BChir, has more than 25 years of experience in the global pharmaceutical industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Dr. Levin is Chief Executive Officer of Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain. Prior to joining Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Previously, he was a member of the Executive Committee of Bristol-Myers Squibb (NYSE:BMY) where he had global responsibilities for strategy, alliances and transactions. In this role, he devised and led BMY’s “String of Pearls” strategy, which resulted in the transformation of the company. Prior to BMY, he was Head of Global Business Development and Strategic Alliances at Novartis (NYSE:NVS). In this role, he established and managed strategic collaborations with multiple companies around the world. Dr. Levin has served on a number of public and private company boards, and currently serves on the Board of Directors of Biocon Ltd. (NSE:BIOCON) and privately-held ZappRx. Dr. Levin holds a Bachelor’s Degree in Zoology and was awarded a Masters of Arts and a Doctorate in the structure of Chromatin from the University of Oxford. He also received Bachelor of Medicine and Bachelor of Surgery degrees from the University of Cambridge. He has practiced internal medicine at University Hospitals in England, Switzerland and South Africa.
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining, Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
From 1999-2002 Mr. Sekhri worked for Novartis AG, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development - a department he established to ensure the differential competitive advantage of Novartis' pipeline.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.
Mr. Sekhri has been a Director on more than 24 private and public company Boards and is currently a member of the Board of Directors of Veeva Systems Inc., and Alpine Immune Sciences Inc. Mr. Sekhri is also the Chairman of the Board of Compugen Ltd., Pharming N.V., Petra Pharma Inc., and Topas Therapeutics GmbH.
Additionally, he serves on several non-profit Boards including the TB Alliance, The English Concert in America (TECA), The Knights, the Caramoor Center for Music and the Arts, and most recently he joined the Board of the Metropolitan Opera. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 20102012, where he is now an active member of their Patrons Council.